BACKGROUND: Resveratrol has demonstrated many beneficial effects against aging, including anti-inflammatory and antioxidant roles. The present study was designed to observe the effects of resveratrol on the dysfunction of dendritic cells (DCs) from COPD patients and its possible mechanism and use in the treatment for COPD. METHODS: Flow cytometry analysis was used to examine the expression of costimulatory markers CD80 and CD86 and ELISA was used to examine the secretion of IFN-α. Expression of miR-34 was examined by using real-time PCR. Expression vector of miR-34, LV3-miR-34 was also constructed and transfected into DCs to observe the effects on functions of DCs. RESULTS: The results showed that there was remarkable upregulation of CD80 and CD86 and secretion of cytokines IFN-α in DCs from COPD patients. Resveratrol displayed a dose-dependent cytotoxicity action over 10 µg/mL and pretreatment with resveratrol inhibited upregulation of CD80 and CD86 and secretion of cytokines IFN-α. Further study showed resveratrol upregulated the expression of miR-34, which inhibited the dysfunction of DCs. CONCLUSION: These proofs suggest that resveratrol inhibited dysfunction of DCs from COPD patients through promoting miR-34.
BACKGROUND:Resveratrol has demonstrated many beneficial effects against aging, including anti-inflammatory and antioxidant roles. The present study was designed to observe the effects of resveratrol on the dysfunction of dendritic cells (DCs) from COPDpatients and its possible mechanism and use in the treatment for COPD. METHODS: Flow cytometry analysis was used to examine the expression of costimulatory markers CD80 and CD86 and ELISA was used to examine the secretion of IFN-α. Expression of miR-34 was examined by using real-time PCR. Expression vector of miR-34, LV3-miR-34 was also constructed and transfected into DCs to observe the effects on functions of DCs. RESULTS: The results showed that there was remarkable upregulation of CD80 and CD86 and secretion of cytokines IFN-α in DCs from COPDpatients. Resveratrol displayed a dose-dependent cytotoxicity action over 10 µg/mL and pretreatment with resveratrol inhibited upregulation of CD80 and CD86 and secretion of cytokines IFN-α. Further study showed resveratrol upregulated the expression of miR-34, which inhibited the dysfunction of DCs. CONCLUSION: These proofs suggest that resveratrol inhibited dysfunction of DCs from COPDpatients through promoting miR-34.
Authors: Massimiliano Agostini; Paola Tucci; Richard Killick; Eleonora Candi; Berna S Sayan; Pia Rivetti di Val Cervo; Pierluigi Nicotera; Frank McKeon; Richard A Knight; Tak W Mak; Gerry Melino Journal: Proc Natl Acad Sci U S A Date: 2011-12-12 Impact factor: 11.205
Authors: Ingel K Demedts; Ken R Bracke; Geert Van Pottelberge; Dries Testelmans; Geert M Verleden; Frank E Vermassen; Guy F Joos; Guy G Brusselle Journal: Am J Respir Crit Care Med Date: 2007-03-01 Impact factor: 21.405
Authors: John V Gosselink; Shizu Hayashi; W Mark Elliott; Li Xing; Becky Chan; Luojia Yang; Claire Wright; Don Sin; Peter D Paré; John A Pierce; Richard A Pierce; Alex Patterson; Joel Cooper; James C Hogg Journal: Am J Respir Crit Care Med Date: 2010-01-14 Impact factor: 21.405
Authors: Emily M Deal; Katharina Lahl; Carlos F Narváez; Eugene C Butcher; Harry B Greenberg Journal: J Clin Invest Date: 2013-05-01 Impact factor: 14.808
Authors: Christine M Freeman; Fernando J Martinez; MeiLan K Han; Theresa M Ames; Stephen W Chensue; Jill C Todt; Douglas A Arenberg; Catherine A Meldrum; Christi Getty; Lisa McCloskey; Jeffrey L Curtis Journal: Am J Respir Crit Care Med Date: 2009-09-03 Impact factor: 21.405
Authors: Pierachille Santus; Maurizio Rizzi; Dejan Radovanovic; Andrea Airoldi; Andrea Cristiano; Rosalynn Conic; Stephen Petrou; Paolo Daniele Maria Pigatto; Nicola Bragazzi; Delia Colombo; Mohamad Goldust; Giovanni Damiani Journal: Biomed Res Int Date: 2018-09-23 Impact factor: 3.411